GlassScriptPhysician profile
Kent Kyger
NPI 1932217429
$763.84
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $300 · 2021: $233.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $166.96 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $121.79 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $65.15 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $54.11 | 2019 | |
| Bausch Health US, LLC | $42.00 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $40.63 | 2021 | |
| Ironshore Pharmaceuticals INC. | $34.99 | 2019 | |
| Abbvie INC. | $29.25 | 2021 | |
| Adlon Therapeutics L.P. | $29.22 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.42 | 2021 | |
| Harmony Biosciences LLC | $21.77 | 2020 | |
| Shire North American Group INC | $20.10 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.82 | 2021 | |
| Tris Pharma INC | $18.20 | 2020 | |
| Noven Therapeutics, LLC | $17.13 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $16.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.94 | 2020 | |
| Validus Pharmaceuticals LLC | $13.39 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Kyger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.